Biological variation of insulin resistance, testosterone and cardiovascular risk factors in women with polycystic ovary syndrome: modification with rimonabant compared to metformin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN75758249

Enrollment

Registered

2007-10-31

Start date

2006-09-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PolyCystic Ovary Syndrome (PCOS) Nutritional, Metabolic, Endocrine PolyCystic Ovary Syndrome (PCOS)

Interventions

Rimonabant 20 mg (oral) daily or metformin 500 mg (oral) three times a day (tds) for 3 months.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Polycystic ovarian syndrome 2. Body Mass Index (BMI) greater than 30 kg/m^2

Exclusion criteria

Exclusion criteria: 1. Patient should not be on any drugs 2. Unwilling for General Practitioner (GP) to be informed 3. Diabetic patients 4. Uncompensated hypothyroidism 5. Patients not on barrier contraception 6. History of psychiatric disorder or severe depression 7. Chronic renal failure

Design outcomes

Primary

Measure	Time frame
The following will be assessed at 3 months: 1. The HOMeostasis model Assessment of Insulin Resistance (HOMA-IR) 2. Testosterone	—

Secondary

Measure	Time frame
The following will be assessed at 3 months: 1. Waist cirumference 2. Free androgen index	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 9, 2026